Skip to Main Content

Transfer Pricing & Tax Controversy in Healthcare

Across the globe, Brattle provides expert testimony and consulting services on behalf of biologic, pharmaceutical, and medical device firms in disputes between the taxpayer and taxing authority.

Our work addresses standard transfer pricing questions – such as the proper application of the best transfer pricing methodology – as well as economic analyses of the industry and its value drivers, entry barriers, and system profits.


Below is a list of representative engagements for our Transfer Pricing & Tax Controversy in Healthcare practice.

Transfer price assessment for blockbuster drugs

In GlaxoSmithKline Holdings (Americas) v. Commissioner, we supported several economic and industry experts in assessing the appropriate transfer price between the UK and the US for blockbuster drugs originally developed in the UK and ultimately sold in the US.

Market impact analysis for proposed opioid surcharge

In Healthcare Distribution Alliance v. Howard A. Zucker, in his official capacity as Commissioner of Health of New York; and Barbara D. Underwood, in her official capacity as the Attorney General of New York, we supported expert declarations that analyzed the expected market impacts of a proposed surcharge on opioid products imported into New York.

News & Knowledge